{"result": "(\"entity\"<|>OBESIDAD<|>EVENT<|>Obesidad is a medical condition characterized by excessive body fat that increases the risk of health problems.)\n##\n(\"entity\"<|>TRATAMIENTO<|>EVENT<|>Tratamiento refers to the medical interventions aimed at managing or curing a disease, in this case, obesity.)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Alhamia Prison is a facility where individuals may be held, relevant in the context of treatment and health management.)\n##\n(\"entity\"<|>POMC<|>ORGANIZATION<|>POMC (pro-opiomelanocortin) is a precursor polypeptide that plays a role in regulating appetite and energy balance.)\n##\n(\"relationship\"<|>LORCASERINA<|>OBESIDAD<|>Lorcaserina is a medication used to treat obesity<|>8)\n##\n(\"relationship\"<|>TRATAMIENTO<|>OBESIDAD<|>Tratamiento is aimed at managing obesity through various medical interventions<|>7)\n##\n(\"relationship\"<|>POMC<|>LORCASERINA<|>Lorcaserina acts on neurons containing POMC to help regulate appetite<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: apneas del sueño, etc.)5, siempre asociadas a medidas\ny ejercicio) es suficiente para reducir el impacto de las\ncomorbilidades asociadas a la obesidad1. Ese objetivo                        dietéticas y cambios en el estilo de vida. De la misma\nparece asumible y fácilmente factible a corto plazo para                     manera, si tras 12-16 semanas de tratamiento activo el\nla mayoría de los       pacientes motivados. Sin embargo,                    paciente no pierde al menos un 5% del peso inicial y/o\nmantener el peso perdido constituye uno de los princi-                       aparecen efectos indeseables graves, se aconseja la reti-\npales desafíos en una situación biológica y ambiental                        rada del tratamiento farmacológico.\ndesfavorable, ya que la recuperación ponderal suele ser                      2.  Fármacos comercializados\nla norma para la mayoría de las personas que han in-\ntentado perder peso y mantenerlo a largo plazo2.                                 no disponibles en Europa\n   En este escenario, disponer de un tratamiento far-                          La FDA (Food and Drug Administration) ha aprobado\nmacológico podría garantizar ese objetivo, si bien has-                      el empleo en Estados Unidos del tratamiento con lor-\nta ahora la aparición de efectos secundarios graves                          caserina y la combinación de fentermina y topiramato\nasociados a la toma de fármacos para el control del                          para el tratamiento de la obesidad. Sin embargo, han\napetito y el peso corporal en el último siglo, ha motiva-                    sido rechazados por la Agencia Europa del Medica-\ndo la retirada comercial sucesiva en estos años3, 4 (tabla                   mento (EMA) porque se consideró que los riesgos su-\n1). Por estos motivos, las agencias reguladoras se han                       peraban a los beneficios esperados.\nmostrado muy cautas a la hora de aprobar nuevos fár-\nmacos para el tratamiento de la obesidad.                                    2.1.   Lorcaserina (Belviq®)\n   En la estrategia terapéutica para el tratamiento de la\nobesidad se contempla que, para que un fármaco sea                             Lorcaserina es un agonista del receptor de serotoni-\nconsiderado efectivo para tratar la obesidad, debe cum-                      na muy específico del subtipo 5HT2c implicado en la\nplir los siguientes requisitos: a) que alcance una diferen-                  inhibición de la vía anorexígena a través de la estimula-\ncia de peso significativa respecto a un placebo > 5% al                      ción que contienen neuronas con pro-opiomelanocor-\nfinalizar un año de tratamiento, y b) que el porcentaje                      tina (POMC). A diferencia de otros fármacos serotoni-\nde sujetos que pierdan más de un 5% de peso supere al                        nérgicos    (dexfenfluramina,       fenfluramina)      lorcaserina\n35% de los casos tratados activamente respecto al pla-                       no tendría supuestos efectos a nivel valvular o de hiper-\ncebo (aproximadamente el doble de pacientes que en el                        tensión pulmonar (ligado a subtipos de receptor 5A o\ngrupo placebo). De la misma manera, las indicaciones                         5B), lo cual supone una gran ventaja teórica.\n\n\n\n                                                                       133\n---\n 134      BLOQUE: ALTERACIONES DE LA ENERGÍA\n\n\n\nTabla 1.    Fármacos empleados para el tratamiento de la obesidad y razones para su retirada commercial\n\n\n\n         Fármaco                      Año                                       Razones para la retirada (año)\n    Dinitrofenol                 1930                  Riesgo de neuropatía y cataratas\n    Anfetaminas                  1936                  Dependencia y abuso. Efectos cardiovasculares potencialmente graves.\n\n\n\n    Aminorex                     1965                  Hipertensión pulmonar (1968)\n    Mazindol                     1970                  Suspendida 1993 (Australia)\n\n\n\n    Fenfluramina                 1963 Europa           Enfermedad valvular cardiaca Hipertensión pulmonar (1997)\n                                 1973 EEUU\n\n\n\n    Dexfenfluramina              1985 Europa           Enfermedad valvular cardiaca Hipertensión pulmonar (1997)\n                                 1996 EEUU\n\n\n\n    Sibutramina                  1997 EEUU             Enfermedad cardiovascular (2010)\n                                 2001 Europa\n\n\n\n    Rimonabant                   2006 Europa           Alteraciones psiquiátricas graves (2009)\n\n\n\n   La tolerabilidad y eficacia de lorcaserina han sido                      FDA, pese a su eficacia modesta, debido a su bajo\nevaluadas en tres ensayos clínicos aleatorizados doble                      perfil de riesgo. Sin embargo, la EMA no ha conside-\nciego frente a placebo. El Estudio BLOSSOM (Behavio-                        rado su comercialización debido a la falta de especifi-\nral Modification and Lorcaserin\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>FDA<|>ORGANIZATION<|>The FDA (Food and Drug Administration) is a regulatory agency in the United States responsible for approving medications and ensuring their safety and efficacy.)\n##\n(\"entity\"<|>EMA<|>ORGANIZATION<|>The EMA (European Medicines Agency) is a regulatory agency in Europe that evaluates and supervises medicinal products.)\n##\n(\"entity\"<|>LORCASERINA<|>ORGANIZATION<|>Lorcaserina is a medication approved by the FDA for the treatment of obesity, acting as a serotonin receptor agonist.)\n##\n(\"entity\"<|>FENTERMINE<|>ORGANIZATION<|>Fentermina is a medication used in combination with topiramate for the treatment of obesity.)\n##\n(\"entity\"<|>TOPIRAMATO<|>ORGANIZATION<|>Topiramato is a medication used in combination with fentermine for the treatment of obesity.)\n##\n(\"entity\"<|>DINITROFENOL<|>ORGANIZATION<|>Dinitrofenol is a drug that was used for weight loss but was withdrawn due to risks of neuropathy and cataracts.)\n##\n(\"entity\"<|>ANFETAMINAS<|>ORGANIZATION<|>Anfetaminas are stimulants that were used for weight loss but were withdrawn due to dependence and potential cardiovascular effects.)\n##\n(\"entity\"<|>MAZINDOL<|>ORGANIZATION<|>Mazindol is a medication that was used for weight loss and was suspended in Australia in 1993.)\n##\n(\"entity\"<|>FENFLURAMINA<|>ORGANIZATION<|>Fenfluramina is a drug that was used for weight loss but was withdrawn due to valvular heart disease and pulmonary hypertension.)\n##\n(\"entity\"<|>DEXFENFLURAMINA<|>ORGANIZATION<|>Dexfenfluramina is a drug that was used for weight loss but was withdrawn due to valvular heart disease and pulmonary hypertension.)\n##\n(\"entity\"<|>SIBUTRAMINA<|>ORGANIZATION<|>Sibutramina is a medication that was used for weight loss but was withdrawn due to cardiovascular disease risks.)\n##\n(\"entity\"<|>RIMONABANT<|>ORGANIZATION<|>Rimonabant is a drug that was used for weight loss but was withdrawn due to severe psychiatric disorders.)\n##\n(\"relationship\"<|>FDA<|>LORCASERINA<|>The FDA approved Lorcaserina for the treatment of obesity in the United States<|>8)\n##\n(\"relationship\"<|>EMA<|>LORCASERINA<|>The EMA rejected the commercialization of Lorcaserina due to safety concerns<|>8)\n##\n(\"relationship\"<|>FENTERMINE<|>TOPIRAMATO<|>Fentermina is used in combination with Topiramato for the treatment of obesity<|>7)\n##\n(\"relationship\"<|>DINITROFENOL<|>FDA<|>Dinitrofenol was withdrawn by the FDA due to risks associated with its use<|>6)\n##\n(\"relationship\"<|>ANFETAMINAS<|>FDA<|>Anfetaminas were withdrawn by the FDA due to dependence and cardiovascular risks<|>6)\n##\n(\"relationship\"<|>MAZINDOL<|>FDA<|>Mazindol was suspended by the FDA in Australia<|>5)\n##\n(\"relationship\"<|>FENFLURAMINA<|>FDA<|>Fenfluramina was withdrawn by the FDA due to serious health risks<|>6)\n##\n(\"relationship\"<|>DEXFENFLURAMINA<|>FDA<|>Dexfenfluramina was withdrawn by the FDA due to serious health risks<|>6)\n##\n(\"relationship\"<|>SIBUTRAMINA<|>FDA<|>Sibutramina was withdrawn by the FDA due to cardiovascular risks<|>6)\n##\n(\"relationship\"<|>RIMONABANT<|>FDA<|>Rimonabant was withdrawn by the FDA due to severe psychiatric disorders<|>6)\n<|COMPLETE|>"}]}